Low-dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma

Massimiliano Cadamuro, Gaia Spagnuolo, Luisa Sambado, Stefano Indraccolo, Giorgia Nardo, Antonio Rosato, Simone Brivio, Chiara Caslini, Tommaso Stecca, Marco Massani, Nicolò Bassi, Eugenio Novelli, Carlo Spirli, Luca Fabris, Mario Strazzabosco

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Nuclear expression of the calcium-binding protein S100A4 is a biomarker of increased invasiveness in cholangiocarcinoma, a primary liver cancer with scarce treatment opportunities and dismal prognosis. In this study, we provide evidence that targeting S100A4 nuclear import by low-dose paclitaxel, a microtubulestabilizing agent, inhibits cholangiocarcinoma invasiveness and metastatic spread. Administration of low-dose paclitaxel to established (EGI-1) and primary (CCA-TV3) cholangiocarcinoma cell lines expressing nuclear S100A4 triggered a marked reduction in nuclear expression of S100A4 without modifying its cytoplasmic levels, an effect associated with a significant decrease in cell migration and invasiveness. While low-dose paclitaxel did not affect cellular proliferation, apoptosis, or cytoskeletal integrity, it significantly reduced SUMOylation of S100A4, a critical posttranslational modification that directs its trafficking to the nucleus. This effect of low-dose paclitaxel was reproduced by ginkolic acid, a specific SUMOylation inhibitor. Downregulation of nuclear S100A4 by low-dose paclitaxel was associated with a strong reduction in RhoA and Cdc42 GTPase activity, MT1-MMP expression, and MMP-9 secretion. In an SCID mouse xenograft model, low-dose metronomic paclitaxel treatment decreased lung dissemination of EGI-1 cells without significantly affecting their local tumor growth. In the tumor mass, nuclear S100A4 expression by cholangiocarcinoma cells was significantly reduced, whereas rates of proliferation and apoptosis were unchanged. Overall, our findings highlight nuclear S100A4 as a candidate therapeutic target in cholangiocarcinoma and establish a mechanistic rationale for the use of low-dose paclitaxel in blocking metastatic progression of cholangiocarcinoma.

Original languageEnglish
Pages (from-to)4775-4784
Number of pages10
JournalCancer Research
Volume76
Issue number16
DOIs
Publication statusPublished - Aug 15 2016

Fingerprint

Cell Nucleus Active Transport
Cholangiocarcinoma
Paclitaxel
Neoplasm Metastasis
Sumoylation
Apoptosis
Matrix Metalloproteinase 14
Calcium-Binding Proteins
SCID Mice
GTP Phosphohydrolases
Post Translational Protein Processing
Liver Neoplasms
Matrix Metalloproteinases
Heterografts
Cell Movement
Neoplasms
Down-Regulation
Biomarkers
Cell Proliferation
Cell Line

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Low-dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma. / Cadamuro, Massimiliano; Spagnuolo, Gaia; Sambado, Luisa; Indraccolo, Stefano; Nardo, Giorgia; Rosato, Antonio; Brivio, Simone; Caslini, Chiara; Stecca, Tommaso; Massani, Marco; Bassi, Nicolò; Novelli, Eugenio; Spirli, Carlo; Fabris, Luca; Strazzabosco, Mario.

In: Cancer Research, Vol. 76, No. 16, 15.08.2016, p. 4775-4784.

Research output: Contribution to journalArticle

Cadamuro, M, Spagnuolo, G, Sambado, L, Indraccolo, S, Nardo, G, Rosato, A, Brivio, S, Caslini, C, Stecca, T, Massani, M, Bassi, N, Novelli, E, Spirli, C, Fabris, L & Strazzabosco, M 2016, 'Low-dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma', Cancer Research, vol. 76, no. 16, pp. 4775-4784. https://doi.org/10.1158/0008-5472.CAN-16-0188
Cadamuro, Massimiliano ; Spagnuolo, Gaia ; Sambado, Luisa ; Indraccolo, Stefano ; Nardo, Giorgia ; Rosato, Antonio ; Brivio, Simone ; Caslini, Chiara ; Stecca, Tommaso ; Massani, Marco ; Bassi, Nicolò ; Novelli, Eugenio ; Spirli, Carlo ; Fabris, Luca ; Strazzabosco, Mario. / Low-dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma. In: Cancer Research. 2016 ; Vol. 76, No. 16. pp. 4775-4784.
@article{5a162aee7f9e4da490dad724f3d724f7,
title = "Low-dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma",
abstract = "Nuclear expression of the calcium-binding protein S100A4 is a biomarker of increased invasiveness in cholangiocarcinoma, a primary liver cancer with scarce treatment opportunities and dismal prognosis. In this study, we provide evidence that targeting S100A4 nuclear import by low-dose paclitaxel, a microtubulestabilizing agent, inhibits cholangiocarcinoma invasiveness and metastatic spread. Administration of low-dose paclitaxel to established (EGI-1) and primary (CCA-TV3) cholangiocarcinoma cell lines expressing nuclear S100A4 triggered a marked reduction in nuclear expression of S100A4 without modifying its cytoplasmic levels, an effect associated with a significant decrease in cell migration and invasiveness. While low-dose paclitaxel did not affect cellular proliferation, apoptosis, or cytoskeletal integrity, it significantly reduced SUMOylation of S100A4, a critical posttranslational modification that directs its trafficking to the nucleus. This effect of low-dose paclitaxel was reproduced by ginkolic acid, a specific SUMOylation inhibitor. Downregulation of nuclear S100A4 by low-dose paclitaxel was associated with a strong reduction in RhoA and Cdc42 GTPase activity, MT1-MMP expression, and MMP-9 secretion. In an SCID mouse xenograft model, low-dose metronomic paclitaxel treatment decreased lung dissemination of EGI-1 cells without significantly affecting their local tumor growth. In the tumor mass, nuclear S100A4 expression by cholangiocarcinoma cells was significantly reduced, whereas rates of proliferation and apoptosis were unchanged. Overall, our findings highlight nuclear S100A4 as a candidate therapeutic target in cholangiocarcinoma and establish a mechanistic rationale for the use of low-dose paclitaxel in blocking metastatic progression of cholangiocarcinoma.",
author = "Massimiliano Cadamuro and Gaia Spagnuolo and Luisa Sambado and Stefano Indraccolo and Giorgia Nardo and Antonio Rosato and Simone Brivio and Chiara Caslini and Tommaso Stecca and Marco Massani and Nicol{\`o} Bassi and Eugenio Novelli and Carlo Spirli and Luca Fabris and Mario Strazzabosco",
year = "2016",
month = "8",
day = "15",
doi = "10.1158/0008-5472.CAN-16-0188",
language = "English",
volume = "76",
pages = "4775--4784",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Low-dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma

AU - Cadamuro, Massimiliano

AU - Spagnuolo, Gaia

AU - Sambado, Luisa

AU - Indraccolo, Stefano

AU - Nardo, Giorgia

AU - Rosato, Antonio

AU - Brivio, Simone

AU - Caslini, Chiara

AU - Stecca, Tommaso

AU - Massani, Marco

AU - Bassi, Nicolò

AU - Novelli, Eugenio

AU - Spirli, Carlo

AU - Fabris, Luca

AU - Strazzabosco, Mario

PY - 2016/8/15

Y1 - 2016/8/15

N2 - Nuclear expression of the calcium-binding protein S100A4 is a biomarker of increased invasiveness in cholangiocarcinoma, a primary liver cancer with scarce treatment opportunities and dismal prognosis. In this study, we provide evidence that targeting S100A4 nuclear import by low-dose paclitaxel, a microtubulestabilizing agent, inhibits cholangiocarcinoma invasiveness and metastatic spread. Administration of low-dose paclitaxel to established (EGI-1) and primary (CCA-TV3) cholangiocarcinoma cell lines expressing nuclear S100A4 triggered a marked reduction in nuclear expression of S100A4 without modifying its cytoplasmic levels, an effect associated with a significant decrease in cell migration and invasiveness. While low-dose paclitaxel did not affect cellular proliferation, apoptosis, or cytoskeletal integrity, it significantly reduced SUMOylation of S100A4, a critical posttranslational modification that directs its trafficking to the nucleus. This effect of low-dose paclitaxel was reproduced by ginkolic acid, a specific SUMOylation inhibitor. Downregulation of nuclear S100A4 by low-dose paclitaxel was associated with a strong reduction in RhoA and Cdc42 GTPase activity, MT1-MMP expression, and MMP-9 secretion. In an SCID mouse xenograft model, low-dose metronomic paclitaxel treatment decreased lung dissemination of EGI-1 cells without significantly affecting their local tumor growth. In the tumor mass, nuclear S100A4 expression by cholangiocarcinoma cells was significantly reduced, whereas rates of proliferation and apoptosis were unchanged. Overall, our findings highlight nuclear S100A4 as a candidate therapeutic target in cholangiocarcinoma and establish a mechanistic rationale for the use of low-dose paclitaxel in blocking metastatic progression of cholangiocarcinoma.

AB - Nuclear expression of the calcium-binding protein S100A4 is a biomarker of increased invasiveness in cholangiocarcinoma, a primary liver cancer with scarce treatment opportunities and dismal prognosis. In this study, we provide evidence that targeting S100A4 nuclear import by low-dose paclitaxel, a microtubulestabilizing agent, inhibits cholangiocarcinoma invasiveness and metastatic spread. Administration of low-dose paclitaxel to established (EGI-1) and primary (CCA-TV3) cholangiocarcinoma cell lines expressing nuclear S100A4 triggered a marked reduction in nuclear expression of S100A4 without modifying its cytoplasmic levels, an effect associated with a significant decrease in cell migration and invasiveness. While low-dose paclitaxel did not affect cellular proliferation, apoptosis, or cytoskeletal integrity, it significantly reduced SUMOylation of S100A4, a critical posttranslational modification that directs its trafficking to the nucleus. This effect of low-dose paclitaxel was reproduced by ginkolic acid, a specific SUMOylation inhibitor. Downregulation of nuclear S100A4 by low-dose paclitaxel was associated with a strong reduction in RhoA and Cdc42 GTPase activity, MT1-MMP expression, and MMP-9 secretion. In an SCID mouse xenograft model, low-dose metronomic paclitaxel treatment decreased lung dissemination of EGI-1 cells without significantly affecting their local tumor growth. In the tumor mass, nuclear S100A4 expression by cholangiocarcinoma cells was significantly reduced, whereas rates of proliferation and apoptosis were unchanged. Overall, our findings highlight nuclear S100A4 as a candidate therapeutic target in cholangiocarcinoma and establish a mechanistic rationale for the use of low-dose paclitaxel in blocking metastatic progression of cholangiocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=84982104852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982104852&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-16-0188

DO - 10.1158/0008-5472.CAN-16-0188

M3 - Article

VL - 76

SP - 4775

EP - 4784

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 16

ER -